FDA still vague over US biosimilars pathway as Abbott "pleads the Fifth"
This article was originally published in SRA
For a law that is supposed to open the door to cheaper versions of branded biologic medicines, the US biosimilars legislation is turning out to be surprisingly vague in a number of respects, to the extent that it could undermine confidence in the new biosimilar approval pathway.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.